Publications

Submitted by ctuttle on
Go back to Resources

First Safety & Immunogenicity Data from a FIH, Placebo-controlled, Dose escalation Trial of a Recombinant Vesicular Stomatitis Virus based Lassa Fever Vaccine in Healthy Adults

Nov-23

Conference Paper

Authors:

Malkin E,
Baden, L,
Kieh M,
Fitz Patrick D,
Diemert D,
Mutua G,
Philiponis V,
Zaric M,
Hunt D,
Barin B,
Engelbrecht M,
Malherbe M,
Walker K,
Lehrman J,
Fast P,
Parks C,
Gupta SB

Secondary:
ASTMH 72nd Annual Meeting

Location:
Chicago, IL

URL:
https://www.iavi.org/wp-content/uploads/2023/11/C102_ASTMH_Poster_Chicago2023.pdf

Abstract:
<p>IAVI is developing a Lassa Fever vaccine using the attenuated chimeric VSV design (rVSVΔG-LASV-GPC) also used in the licensed Ebola Zaire vaccine, ERVEBO® (Merck). The Lassa virus (LASV) vaccine was generated by replacing the VSV surface G protein with the LASV glycoprotein complex (GPC). Vaccination with 2x105 or 2x107 pfus protected non-human primates from infection with LASV. A Phase 1 clinical trial enrolled 113 participants, 52 in a dose escalation (US) and 61 in a dose expansion (60 in Liberia, 1 in US). The dose escalation is unblinded and the dose expansion remains blinded.</p>

Go back to Resources